

Zsofia Stadler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5738734/publications.pdf>

Version: 2024-02-01

35
papers

3,037
citations

430874

18
h-index

361022

35
g-index

36
all docs

36
docs citations

36
times ranked

5615
citing authors

#	ARTICLE	IF	CITATIONS
1	PD-1 Blockade in Mismatch Repairâ€“Deficient, Locally Advanced Rectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 2363-2376.	27.0	588
2	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <i>Nature Genetics</i> , 2020, 52, 1219-1226.	21.4	367
3	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
4	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. <i>JAMA Oncology</i> , 2016, 2, 104.	7.1	270
5	Germline <i>BRCA</i> Mutations Denote a Clinicopathologic Subset of Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 2115-2121.	7.0	263
6	Counselling framework for moderate-penetrance cancer-susceptibility mutations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 581-588.	27.6	258
7	Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. <i>JCO Precision Oncology</i> , 2017, 2017, 1-17.	3.0	209
8	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2021, 39, 2698-2709.	1.6	83
9	Immunohistochemical Staining for DNA Mismatch Repair Proteins in Intestinal Tract Carcinoma. <i>American Journal of Surgical Pathology</i> , 2011, 35, 447-454.	3.7	82
10	Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoeexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency. <i>Modern Pathology</i> , 2013, 26, 131-138.	5.5	82
11	Germline EGFR T790M Mutation Found in Multiple Members of a Familial Cohort. <i>Journal of Thoracic Oncology</i> , 2014, 9, 554-558.	1.1	63
12	Risk of metachronous breast cancer after <i>BRCA</i> mutationâ€“associated ovarian cancer. <i>Cancer</i> , 2013, 119, 1344-1348.	4.1	58
13	Susceptibility Loci Associated with Specific and Shared Subtypes of Lymphoid Malignancies. <i>PLoS Genetics</i> , 2013, 9, e1003220.	3.5	44
14	Assessment of SLX4 Mutations in Hereditary Breast Cancers. <i>PLoS ONE</i> , 2013, 8, e66961.	2.5	37
15	Clinical Calculator Based on Molecular and Clinicopathologic Characteristics Predicts Recurrence Following Resection of Stage I-III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 911-919.	1.6	34
16	Risk-Reducing Bilateral Salpingo-Oophorectomy for Ovarian Cancer: A Review and Clinical Guide for Hereditary Predisposition Genes. <i>JCO Oncology Practice</i> , 2022, 18, 201-209.	2.9	34
17	Germline <i>SDHA</i> mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002584.	1.2	33
18	Toward automation of germline variant curation in clinical cancer genetics. <i>Genetics in Medicine</i> , 2019, 21, 2116-2125.	2.4	27

#	ARTICLE	IF	CITATIONS
19	Breast and Prostate Cancer Risks for Male <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variant Carriers Using Polygenic Risk Scores. <i>Journal of the National Cancer Institute</i> , 2022, 114, 109-122.	6.3	19
20	Association of breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 117-134.	2.5	18
21	Tumor-Infiltrating Lymphocytes, Tumor Mutational Burden, and Genetic Alterations in Microsatellite Unstable, Microsatellite Stable, or Mutant <i>POLE/POLD1</i> Colon Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 817-826.	3.0	18
22	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous <i>BRCA1</i> or <i>BRCA2</i> pathogenic variant. <i>Genetics in Medicine</i> , 2021, 23, 1726-1737.	2.4	16
23	Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery. <i>JAMA Network Open</i> , 2021, 4, e2133457.	5.9	16
24	Prevalence and Characterization of Biallelic and Monoallelic <i>NTHL1</i> and <i>MSH3</i> Variant Carriers From a Pan-Cancer Patient Population. <i>JCO Precision Oncology</i> , 2021, 5, 455-465.	3.0	10
25	Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. <i>Oncologist</i> , 2015, 20, 992-1000.	3.7	8
26	A Coordinated Clinical Center for Young Onset Colorectal Cancer. <i>Oncologist</i> , 2021, 26, 625-629.	3.7	8
27	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. <i>JCO Oncology Practice</i> , 2022, 18, e462-e471.	2.9	8
28	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	3.0	7
29	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. <i>Journal of the National Cancer Institute</i> , 2021, , .	6.3	6
30	Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, 167-174.	2.3	3
31	Quantitative assessment of tumor-infiltrating lymphocytes in mismatch repair proficient colon cancer. <i>Oncolmmunology</i> , 2020, 9, 1841948.	4.6	3
32	<i>ATM</i> Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. <i>Journal of the National Cancer Institute</i> , 2022, 114, 761-770.	6.3	3
33	Intratumoral T-cell repertoires in DNA mismatch repair-proficient and -deficient colon tumors containing high or low numbers of tumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2022, 11, 2054757.	4.6	3
34	Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. <i>Clinical Colorectal Cancer</i> , 2022, , .	2.3	2
35	Primary Clonal Loss of Mismatch Repair Protein on Immunohistochemistry: A Pattern of Abnormality That Warrants Genetic Workup. <i>JCO Precision Oncology</i> , 2022, , .	3.0	1